OCGN — Ocugen, Inc.
$0.7397-6.37%
Last close: · regular session
After-hours $0.7448 +0.69% ·
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for OCGN in the TickerWise workspace.
Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD). OCU200: A novel fusion protein, presently undergoing preclinical evaluation for its potential in treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains significant strategic collaborations, including a partnership with CanSino Biologics Inc. for the joint development and manufacturing of gene therapies, and an alliance with Bharat Biotech for the commercialization of COVAXIN within the United States market. The company's corporate headquarters are situated in Malvern, Pennsylvania.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ Capital Market
- Employees: 95
- Website: https://www.ocugen.com
Latest SEC filings for OCGN
Latest OCGN news
- Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa Read article
- Did Ocugen, Inc. Insiders Breach their Fiduciary Duties to Shareholders? Read article
- Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate Read article
- Ocugen to Participate in Upcoming Scientific Conferences Read article
- Ocugen to Participate in Upcoming October Investor and Industry Conferences Read article
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.